This underscores the importance of studies on PD-1 expression in the lymphoma microenvironment to support the rationale of immunotherapies and the need to monitor tumor-expressed PD-1 protein to optimize treatment efficacy. This evidence concerns the gene PDCD1 and lymphoma.